Background and Aims: X-linked inhibitor of apoptosis proteinassociated factor 1 (XAF1) is a tumor suppressor that can sensitize cancer cell to apoptosis. Intrinsic expression of XAF1 in cancer cell is low. Our purpose is to determine the effect of c-Jun Nterminal kinase 1 (JNK1) on XAF1 expression and the putative mechanism. Methods: XAF1 expression in gastrointestinal (GI) cancer cell line AGS and SW1116 was detected by reverse transcription-polymerase chain reaction (PCR), real-time PCR and immunoblotting. The role of JNK1 was assessed by ectopic overexpression with wild-type (JNK1-WT) and dominant-negative (JNK1-DN) JNK1 constructs. The effects of JNK1 activator, interferon (IFN)-a, tumor necrosis factor (TNF)-a and phorbol-12-myristate-13-acetate (PMA), or JNK1 inhibitor, SP600125, were evaluated. An XAF1 promoter reporter pLUC107 with WT or mutated interferon regulatory factor 1-binding element (IRF-E) was used to assess JNK1-induced transcription by dual luciferase assay. Result: Ectopic overexpression of JNK1-WT or treatment with IFN-a, TNF-a and PMA induced whereas SP600125 suppressed intrinsic and induced XAF1 expression. Induction of XAF1 required de novo protein synthesis. Moreover, JNK1 stimulated whereas SP600125 suppressed XAF1 promoter activity. JNK1 stimulated interferon regulatory factor 1 (IRF-1) expression, whereas both IRF-1 small-interfering RNA and site mutation of IRF-E within XAF1 promoter abrogated the effect of JNK1. Conclusion: JNK1 stimulated and mediated the effects of IFN and TNF-a on XAF1 expression through transcriptional regulation by induction of IRF-1. The linkage of JNK1, IRF-1 and XAF1 in the same signal pathway may unravel a novel mechanism in regulation of apoptosis and differentiation of GI cancers.
Introduction
Apoptosis plays a crucial role in maintenance of tissue homeostasis. The resistance to apoptosis, partially conferred by the expression of intrinsic negative regulators, confers to tumorigenesis and chemoresistance (1,2).
X-linked inhibitor of apoptosis protein-associated factor-1 (XAF1) is first identified as an interacting protein of X-linked inhibitor of apoptosis (XIAP) (3) . XAF1 antagonizes the inhibitory effect of XIAP on caspase-3 through physical interaction and causing the inactive cleavage of XIAP (3, 4) , thus functions as a proapoptotic protein.
We and others have reported that overexpression of XAF1 suppresses colon cancer cell growth and increases susceptibility to various apoptotic stimuli (5, 6) .
XAF1 has been defined as an interferon (IFN)-stimulating genes with its expression being inducible by both IFN and tumor necrosis factor (TNF)-a (7) . IFN induces XAF1 expression through either the interaction with the interferon regulatory factor 1-binding element (IRF-E) or demethylation of the CpG sites within XAF1 promoter (8, 9) . In fact, reactivation of endogenous XAF1 plays critical role in TNF-related apoptosis-inducing ligand (TRAIL)-induced cell death since XAF1 knockdown cell lines completely lost their IFN-b-mediated TRAIL sensitivity (9) . In addition, XAF1 functions as an alternative pathway for TNF-a-induced apoptosis by translocating to the mitochondria and promoting XIAP inactivation (4) . Therefore, XAF1 appears to be a mediator or effector of cytokine-induced apoptosis.
c-Jun N-terminal kinase (JNK) plays a pivotal role in cytokineinduced apoptosis (10) (11) (12) (13) (14) . JNK proteins are encoded by three genes. The Jnk1 and Jnk2 genes are expressed ubiquitously. In contrast, the Jnk3 gene has a more limited pattern of expression and is largely restricted to brain, heart and testis (13) . Some reports indicated that JNK1 and JNK2 plays different role in regulating cell proliferation and apoptosis. For example, JNK1 deficiency in mice usually develop intestinal tumors spontaneously wherever JNK2 deficiency in mice lead to inhibition of tumorigenesis (14, 15) . The classical signal pathway for JNKs is to phosphorylate c-Jun protein and to enhance the transcription activity of activator protein-1 (AP-1) (11, 13, 16) . However, accumulating evidences suggest the presence of novel interacting proteins or function pathways of JNKs. For example, p53 protein is able to bind with JNK1 and is therefore stabilized and activated by JNK1 in stressed cells (17) , whereas the activator of protein kinase C, phorbol-12-myristate-13-acetate (PMA), is able to activate JNK1 within the context of apoptosis (18) .
In addition to apoptosis, JNK1 also mediates the differentiation of gastrointestinal (GI) tissues. Besides the occurrence of spontaneous tumors, the normal mucosa in JNK1-deficient mice showed decreased cell differentiation and increased cell proliferation. Immunohistochemical staining showed that JNK1 was highly expressed in the differentiation compartment of the intestinal mucosa and that the expression of JNK1 was significantly decreased in both human colonic and mouse intestinal tumors (14) . Treatment of colon cancer cells with pro-differentiation agent, sodium butyrate, increased JNK1 activity and the phosphorylation of c-Jun together with the induction of intestinal alkaline phosphatase activity (19) .
In the present study, we reported that JNK1 induced XAF1 expression. JNK1 induced the expression of interferon regulatory factor 1 (IRF-1) and subsequently upregulated XAF1 expression through transcriptional regulation. Our findings may provide novel understanding on the mechanism for JNK1 to regulate cell apoptosis and differentiation.
Biotechnology (Santa Cruz, CA). JNK inhibitor, SP600125, was the product of Calbiochem (La Jolla, CA).
Cell culture and treatments
Gastric cancer cell line AGS and colon cancer cell line SW1116 were obtained from American Type Culture Collection (Rockville, MD). They were all maintained in RPMI1640 (Life Technologies, Gaithersburg, MD) supplemented with 10% fetal bovine serum and 100 lg/ml streptomycin and 100 U/ml penicillin in a humidified incubator at 37°C with an atmosphere of 5% CO 2 .
Constructs and transient transfection pcDNA3 constructs encoding either wild type (JNK1-WT) or mutated (JNK1-DN) hemagglutinin-tagged human JNK1 complementary DNA (cDNA) has been described before (20) . Luciferase reporter pLUC107-WT and pLUC107-34-MT were both pGL3 plasmids with firefly luciferase gene being driven by WT or À34 site mutated 107 bp promoter of XAF1 gene as described previously (8) . Transient transfection was carried out using the LipofectAMINE 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.
Reverse transcription-polymerase chain reaction Total RNA was extracted from cells using TRIzol Reagent (Gibco BRL, Gaithersburg, MD; Life Technologies). Two micrograms of RNA was reversely transcribed to cDNA by Thermoscript RT system reagent (Gibco BRL) according to the manufacturer's instruction. Polymerase chain reaction (PCR) was performed using 2 ll of resulting cDNA, 0.5 U Hotstart DNA polymerase (Qiagen, Valencia, CA), primers and deoxynucleoside triphosphates in a final volume of 50 ll. The primer sequences were as follows: XAF1, forward: 5#-GAGCTCCACGAGTCCTACTG-3# and reverse: 5#-AAACTCTGAGTCT-GGACAAC-3# (product size: 238 bp) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward: 5#-GACCACAGTCCATGCCATCAC-3# and reverse: 5#-TCCACCACCCTGTTGCTGTA-3# (product size: 453 bp). Hotstart PCR was performed for 34 cycles with 95°C denaturation for 30 min (first cycle), 94°C denaturation for 45 s, 55°C annealing for 45 s and 72°C elongation for 45 s and 10 min (final cycle). Amplification products were of the expected sizes.
Quantitative real-time reverse transcription-PCR Quantitative PCRs were performed using Applied Biosystems Sequence Detection System 7900 (ABI Prism 7900HT, Applied Biosystems, Foster City, CA) with 15 ll mixture composed of Power SYBR GREEN PCR Master Mix (Applied Biosystems), 500 nmol of each primer and $300 ng of cDNA templates. The reactions were carried out with initial denaturation at 95°C for 5 min followed by 45 cycles of 20 s at 94°C, 20 s at 60°C and 40 s at 72°C. A final extension at 72°C for 5 min was included before a temperature ramp from 72 to 95°C at 0.1°C/s with continuous fluorescent acquisition. The copy numbers of XAF1 messenger RNA were quantified by inspection of melt curves and CT values generated in comparing with the internal control, GAPDH. Each sample was duplicated to calculate the mean and standard deviation. The primer sequences for real-time PCR were as follows: XAF1, sense: 5#-AG-CAGGTTGGGTGTACGATG-3# and antisense: 5#-TGAGCTGCATGTC-CAGTTTG-3#, the expected PCR product was 123 bp and GAPDH, sense: 5#-GTCAACGGATTTGGTCGTATTG-3# and antisense: 5#-CTCCTGGAA-GATGGTGATGGG-3# with 216 bp of PCR product. All oligonucleotides were synthesized by Proligo, Singapore, Singapore.
Immunoblotting Whole-cell lysates were prepared from cells with lysis buffer containing protease inhibitors (20 mM Tris-HCl, 1 mM ethylenediaminetetraacetic acid, 1 mM ethylene glycol-bis (2-aminoethylether)-N,N,N#,N#-tetraacetic acid tetrasodium salt, 0.2 mM phenylmethylsulfonyl fluoride, 0.5% NP-40 and 1 lg/ml of leupeptin, aprotinin and pepstatin A). The protein concentration was determined by bicinchoninic acid assay (BCA protein assay kit, Pierce, Rockford, IL) with bovine serum albumin as the standard. Equal aliquots of total cell lysates (30 lg) of each sample were solubilized in sample buffer and electrophoresed on denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel (5% stacking gel and 12% of separating gel). The proteins were then transferred to polyvinylidene difluoride membranes (Millipore Corp., Bedford, MA) using transfer buffer for 2 h. Non-specific binding was blocked with 10 mM, pH 7.6, Tris-HCl buffer saline plus 0.05% Tween-20 containing 3% bovine serum albumin for 1 h at room temperature. The blots were probed with primary antibody for 1 h at room temperature followed by the horseradish peroxidase-conjugated second antibody. Actin was also detected as internal control. Antigen-antibody complexes were visualized by the ECL system (Amersham Biosciences, Little Chalfont Buckinghamshire, UK).
Small RNA interference
The small-interfering RNA (siRNA) duplexes consisting of 21 bp with a two base deoxynucleotide overhang were synthesized commercially (Proligo). The sequences of IRF-1 siRNA was (sense strand) 5#-AACUUUCGCUGUGCCAUGAACdTdT-3# and JNK1 siRNA was (sense strand) 5#-AAGCCCAGUAAUAUAGUAGUAdTdT-3#. c-Jun siRNA was purchased from Santa Cruz Biotechnology. The control siRNA, GL2 (5#-CGUACGCGGAAUACUUCGA-3#), was directed against the luciferase gene. The cells were transfected with siRNA duplexes using Oligofectamine (Invitrogen) as per the manufacturer's instructions (8) .
Dual luciferase reporter assay Dual luciferase assay was performed using the Dual-luciferase Reporter Assay kit (Promega, Madison, WI) as per the manufacturer's instructions. Briefly, 1 Â 10 5 cells were seeded in each well of a 24-well tissue culture plate. The cells were incubated until 70% confluent. Cells in each well were transfected with 0.8 lg of pGL3 basic or pLUC107 reporter plasmid by 1 ll Lipofect-AMINE 2000 reagent. The Renilla luciferase reporter pRL-CMV plasmid (Promega) 0.01 lg per well was cotransfected as the internal control. After transfection for 4 h, cells were transferred into normal medium. To examine the effect of JNK construct, pLUC107 plasmid was cotransfected with JNK1-MT or JNK1-DN. Forty-eight hours later, the cells were treated with passive lysis buffer. Luciferase activities were measured with a luminometer (lumat LB 9507, Berthold, Bad Wildbad, Germany). Firefly luciferase activity value was normalized to that of Renilla. Promoter activity was presented as the fold of relative luciferase units (RLU) comparing with basic pGL3 vector control. RLU 5 values of firefly luciferase unit/values of Renilla luciferase unit standardized by pGL3 basic vector.
Statistical analysis
Results obtained from triplicated dual luciferase experiments were expressed as the mean ± SD. RLU with different treatments were compared using a twotailed Student's t-test and considered significant if P values were ,0.05.
Results

XAF1 expression was upregulated by JNK1
To define the effect of JNK1 on XAF1 expression, we first transfected AGS and SW1116 cells with JNK1-WT and JNK1-DN constructs. As shown in Figure 1A and B, the intrinsic expression of XAF1 was either low (AGS) or undetectable (SW1116). Ectopic overexpression of JNK1 increased the amount of p-JNK1 (p46) and upregulated XAF1 expression at both messenger RNA and protein levels. In contrary, transfection with JNK1-DN construct diminished XAF1 expression in AGS cells. Secondly, we suppressed JNK1 activity with its specific inhibitor, SP600125 (21, 22) . We showed that both 10 and 20 lM of SP600125 were capable of decreasing the concentration of phospho-JNK1 as well as suppressing XAF1 expression in AGS cells with the higher concentration having stronger effect ( Figure 1C ). Finally, we examined the role of a well-defined JNK1 activator, PMA in XAF1 expression (18, 23) , in SW1116 cells since this cell line expressed lower level of XAF1 than AGS cell ( Figure 1A ). We found that the three concentrations of PMA all stimulated XAF1 expression at both messenger RNA and protein levels ( Figure 1D ). However, no dosedependent tendency was observed. Pretreatment of cells with JNK inhibitor abrogated the effect of PMA ( Figure 1D ).
JNK activity was indispensable for XAF1 expression We and others have identified XAF1 as an IFN-stimulating gene with its expression being inducible by both IFNs and TNF-a. To examine whether the effects of IFN and TNF were dependent on JNK1 activation or not, we treated AGS cells with or without JNK inhibitor followed by TNF-a and IFN-a. As shown in Figure 2A and B, both cytokines increased the concentrations of p-JNK1 and XAF1. Pretreatment of cells with JNK inhibitor abolished the effects of TNF-a and IFN-a almost completely. Moreover, we transfected cells with JNK1 siRNA followed by treatment with TNF-a. We showed that JNK1 siRNA decreased JNK1 and p-JNK1 levels and suppressed both endogenous and induced XAF1 expression ( Figure 2C ), indicating the specific role of JNK1 in XAF1 induction.
On the other hand, we incubated cells with a tyrosine phosphatase inhibitor, sodium orthovanadate, to sustain the activity of JNK1 by inhibiting its degradation (24, 25) . We found that this chemical could increase the concentration of phospho-JNK1 ( Figure 2D ). Sodium orthovanadate alone was able to stimulate XAF1 expression while JNK1 upregulates XAF1 expression its pretreatment strengthened the effect of TNF-a, IFN-a and PMA significantly ( Figure 2D ).
JNK1 stimulated XAF1 expression through transcription regulation
To elucidate the mechanism for JNK1 to induce XAF1 expression, we examined the requirement of de novo protein synthesis. We stimulated XAF1 expression with PMA, IFN-a and TNF-a after the pretreatment with protein synthesis inhibitor emetine or cycloheximide. We found that both chemicals had no effect on XAF1 expression as detected by both reverse transcription-PCR and real-time PCR assays ( Figure 3A) . However, they suppressed XAF1 expressions induced by TNF-a, IFN and PMA. This finding suggested that the induction of XAF1 required de novo protein synthesis.
Subsequently, we checked the effect of JNK1 on the transcription activity of a core XAF1 promoter we cloned before (8) . pLUC107 contained 107 bp sequence upstream of ATG translation starting codon including the transcription starting site of XAF1 gene. After cotransfection of pLUC107 with vector control, JNK1-WT or JNK1-DN, dual luciferase assay showed that JNK1-WT increased whereas DN mutated JNK1 suppressed transcription activity of pLUC107 in both AGS and SW1116 cells ( Figure 3B ). The RLU of vector control, JNK1-WT and JNK1-DN were 59.22 ± 7.2, 116.4 ± 8.6 and 35.74 ± 2.33, respectively, in AGS cells and 12.45 ± 1.67, 20.43 ± 1.89 and 5.34 ± 0.88, respectively, in SW1116 cells. Significant difference was found in comparison of both JNK1-WT and JNK1-DN with vector controls in two cell lines. In consistent with the RNA expression levels shown in Figure 1A , pLUC107 promoter activity in SW1116 cell was much lower than that in AGS cell.
Moreover, we tested the effect of JNK inhibitor on the transcription of pLUC107. We found that the RLU of pLUC107 in the absence and presence of SP600125 were 76.25 ± 11.26 and 8.5 ± 1.97, respectively (P , 0.05), in AGS cell ( Figure 3C ).
These results suggested that JNK1 upregulated XAF1 expression through transcription regulation.
JNK1 induced IRF-1 expression
As the upstream modulator of AP-1 transcription complex, JNK1 usually phosphorylated AP-1 components including c-Jun and activating transcription factor 2 (ATF-2), and subsequently triggered the transcription of AP-1 target genes (13, 16, 17) . To investigate if JNK1 induce XAF1 expression through a AP-1-mediated transcription regulation, we first searched as long as l000 bp putative promoter sequence of XAF1 gene upstream of the transcription starting site using TFsearch software (http://molsun1.cbrc.aist.go.jp/research/db/TFSEARCH.html). No typical AP-1-binding element was found. Secondly, we tested if the predominant component of AP-1, c-Jun, was required for XAF1 induction. We transfected cells with c-Jun siRNA followed by treatment with PMA. As shown in Figure 4A , siRNA suppressed the endogenous and PMAinduced c-Jun expression. However, it had only weak effect on the endogenous and no effect on induced XAF1 expression.
We have identified a high affinity with high activity IRF-E in pLUC107 (8) . To define whether JNK1 stimulated XAF1 expression through modulating IRF-1 expression, we treated cells with transfection of JNK1-WT construct, PMA or SP600125 to alter JNK1 activity. As shown in Figure 4B and C, JNK1 overexpression, IFN-a, TNF-a and various concentrations of PMA were all able to increase IRF-1 protein concentration. No dose-dependent induction of IRF-1 was found when the cells being treated with serially diluted PMA. Similarly, suppression of JNK1 activity by SP600125 decreased IRF-1 expression ( Figure 4D ).
IRF-1 was required in JNK1-induced XAF1 transcription
To further determine the requirement of IRF-1 protein in JNK1-stimulated XAF1 expression, we inhibited IRF-1 expression by small RNA interference ( Figure 5A ) followed by assaying the promoter activity of pLUC107. As shown in Figure 5B , IRF-1 siRNA significantly suppressed the transcription activity of pLUC107 in both cell lines tested when comparing with the control siRNA JNK1 upregulates XAF1 expression (P , 0.05). RLU of pLUC107 cotransfected with control versus IRF-1 siRNA were 61.41 ± 6.44 versus 14.12 ± 1.12 in AGS cell and 5.03 ± 0.41 versus 2.18 ± 0.27 in SW1116 cell. The inhibition of IRF-1 abrogated 54% (SW1116) to 77% (AGS) of the promoter activity of pLUC107.
Moreover, we examined the effect of PMA on XAF1 promoter activity in the presence of IRF-1 siRNA. As shown in Figure 5B , PMA treatment in the presence of control siRNA increased promoter activity of pLUC107 significantly. RLU of pLUC107 without versus with PMA were 61.41 ± 6.44 versus 97.37 ± 8.42 in AGS cells and 5.03 ± 0.41 versus 9.37 ± 0.97 in SW1116 cells (P , 0.05 between samples without and with PMA treatments). However, PMA had only weak effect in stimulating pLUC107 transcription in the presence of IRF-1 siRNA. RLU of pLUC107 without versus with PMA was 14.12 ± 1.12 versus 15.21 ± 1.95 in AGS cells and 2.18 ± 0.27 versus 2.31 ± 0.54 in SW1116 cells (P . 0.05 between samples without and with PMA treatments). These results suggested that IRF-1 protein is necessary for JNK1 to induce XAF1 transcription.
Site mutation of IRF-E abrogated JNK1-induced XAF1 transcription The IRF-E is located at À30 to À38 nt region upstream of the ATG translation starting codon of XAF1 gene as underlined in Figure 6A . To test whether JNK1-induced XAF1 transcription was mediated by IRF-1, we mutated the central site (À34 nt) of IRF-E in pLUC107 construct. As shown in Figure 6B and C, À34 mutation abrogated the transcription activity of pLUC107. Then, we treated cells transiently transfected with pLUC107-WT and pLUC107-34-MT with PMA. We found that PMA increased the promoter activity of pLUC107-WT significantly. The RLU of pLUC107-WT without and with PMA were 62.7 ± 9.92 and 108.27 ± 9.27 in AGS cells, respectively (P , 0.05). Similar tendency was found in SW1116 cells ( Figure 6B ). However, PMA could not stimulate transcription of pLUC107-34-MT ( Figure 6B , P . 0.05). Consistently, JNK inhibitor suppressed the transcription activity of pLUC107-WT but could not decrease that of pLUC107-34-MT furthermore ( Figure 6C) . Ã P , 0.05 comparing with the control. # P . 0.05 versus control. The dual luciferase data were mean ± SD of triplicated wells and these figures were the representative of three to four independent experiments with similar results.
Discussion
In this study, we evaluated the effect of JNK1 on XAF1 expression and investigated the underlying mechanism. We showed that overexpression or activation of JNK1 upregulated XAF1 expression. XAF1 expression induced by IFN, TNF and PMA were all JNK1 dependent. In addition, we showed, for the first time, that overexpression or activation of JNK1 induced IRF-1 expression. IRF-1 protein and the integrity of its binding element were all required for JNK1 in inducing XAF1 expression. Our finding provided a novel interpretation for the mechanism in which JNK1 induced apoptosis or differentiation in GI cancers.
We and others have found that expression of XAF1 was downregulated in colon cancers and correlated with advanced stage and high grade of tumor (6, 26, 27) . This was similar to that of JNK1. By using both immunoblot analysis and in vitro kinase assay, Wang et al. (28) reported that the activity of JNK1 was downregulated in the majority of colorectal cancers comparing with the adjacent normal mucosa. These observations suggested that XAF1 was a putative target or effector protein of JNK1 during carcinogenesis of GI cancers. Our finding that both JNK1 and its activators were able to induce XAF1 expression supported this hypothesis.
JNK is one member of mitogen-activated protein kinase family and can be activated when the cells are exposing to stress stimulations such as hypoxia stress and cytokines (10) (11) (12) (13) . JNK1 was induced by and mediated the proapoptotic effect of two predominant proinflammatory cytokines, IFN and TNF-a (10) (11) (12) (13) (14) . Interestingly, this couple of cytokines was the only cytokines reported so far that being able to induce XAF1 (4,7-9). Here, we showed that the effect of both cytokines on XAF1 expression was JNK1 dependent, revealing the sequential association between JNK1 and XAF1 in stress response. Our finding was also supported by a recent report that XAF1 expression was increased temporally in cells in vivo with hypoxic-ischemic (29), Ã P , 0.05 versus control. # P . 0.05 versus control. The dual luciferase data were mean ± SD of triplicated wells and these figures were the representative of three independent experiments in both AGS and SW1116 cells with similar findings.
JNK1 upregulates XAF1 expression a process in which JNK1 played crucial role (30, 31) . Although both the ectopic overexpression and activation of JNK1 were capable of inducing XAF1, the induction of XAF1 might be activation dependent. Overexpression of JNK1 could increase the level of phosphorylated JNK1 together with the increasing of total JNK1 protein (32), whereas SP600125 could only suppress the activation of JNK1 (33) .
Other two members of mitogen-activated protein kinase are p38 and extracellular signal-regulated kinase (ERK). By using specific inhibitor, we found that p38 had no effect on XAF1 expression (data not shown). Unlike JNK1, inhibition but not the activation of ERK increased XAF1 expression in colon cancers (5) . The opposite effect of JNK1 and ERK on XAF1 expression is consistent with their reverse role in regulating cell proliferation and apoptosis (19, 34) . In contrary to the low activity of JNK1 in colon cancers, ERK activation is essential to maintain the growth and malignant phenotype of colon cancer (35, 36) . Inhibition of ERK1/2 phosphorylation decreased soft agar growth and inhibited the transformed phenotype of colon 26 cells in vitro and suppressed the formation of mouse and human colon cancer xenografts (36) .
In the current study, after determining the effect of JNK1 on XAF1 expression, we have presumed that this effect was mediated by the subsequent activation of AP-1 since the major components of AP-1 such as c-Jun and ATF-2 are the earliest reported downstream molecules of JNK1 (13, 16, 17) . However, we could not identify a typical AP-1-binding element around the proximal region of XAF1 promoter through bioinformatic analysis. In addition, suppression of c-Jun, a major component of AP-1, did not abrogate PMA-induced XAF1 expression, suggesting that AP-1 might not be the predominant activator of XAF1 transcription. IRF-1 was the first member identified of the IRF family and has been implicated as a strong tumor suppressor. Oncogene-transformed cultured cell lines can be reverted to their normal phenotype by ectopic expression of IRF-1 (37, 38) . This prodifferentiation effect of IRF-1 is similar to that of JNK1 and XAF1. However, there is no report concerning the correlation between JNK1 and IRF-1 so far. In here, we showed that activation of JNK1 induced IRF-1 expression, indicating a synergized interaction between JNK1 and IRF-1 in regulation of cell growth and differentiation. By using co-immunoprecipitation, we did not find the physical interaction between XAF1 and JNK1, XAF1 and IRF-1 or JNK1 and IRF-1 (data not shown); however, the interaction between JNK1, AP-1 and IRF-1 in regulation of XAF1 expression still desired to be further investigated.
We found that the IRF-E within XAF1 promoter is critical in mediating XAF1 transcription. Suppressing IRF-1 expression by siRNA could suppress the reporter activity of pLUC107. Moreover, sitedirected mutation of IRF-E to block its binding with IRF-1 protein had the similar effect. Both the suppression of IRF-1 protein and the mutation of IRF-E abolished the effect of JNK1 strongly bore out the requirement of IRF-1 during JNK1-induced XAF1 expression.
Taken together, this study delineated the effect and mechanism of JNK1 in upregulating XAF1 in GI cancer cells. JNK1, IRF-1 and XAF1 are linked to the same signal pathway during cytokine stresses and might have played pivotal role in controlling the proliferation and apoptosis of tumor cells under some circumstances.
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